| 1 |
30112997 | Dabigatran Reversal with Idarucizumab in an Emergency Lumbar Puncture: A Case Report. | 2019 |
1 |
| 2 |
31535075 | The (Fab)ulous Destiny of Idarucizumab: Highlighting Its Interference with Urine Protein Immunofixation. | 2019 Jul |
2 |
| 3 |
29534609 | The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination. | 2018 Jul |
1 |
| 4 |
30120649 | Assessment of patients post reversal with idarucizumab. | 2018 Nov |
1 |
| 5 |
28144727 | [Non-vitamin K dependent oral anticoagulants : What is important in intensive care medicine]. | 2017 Mar |
2 |
| 6 |
28210988 | Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases. | 2017 Apr |
1 |
| 7 |
26937198 | Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. | 2016 |
1 |
| 8 |
27543264 | Management of bleeding in patients treated with direct oral anticoagulants. | 2016 Aug 20 |
1 |
| 9 |
26020620 | Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. | 2015 Jul |
2 |
| 10 |
24499559 | Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model. | 2014 Feb 5 |
2 |
| 11 |
25494843 | Specific antidotes in development for reversal of novel anticoagulants: a review. | 2014 |
1 |
| 12 |
23476049 | A specific antidote for dabigatran: functional and structural characterization. | 2013 May 2 |
1 |